Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | SLC25A20 | O43772 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.76 |
| ▸ | GMNN | O75496 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palmitoyl-Carnitine SCHEMBL115183 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL288673 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL19182624 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL8050598 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL288242 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL17164609 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL25373354 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL187668 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Octanoylcarnitine SCHEMBL2915508 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL198686 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048146-A1 | METHODS AND COMPOSITIONS FOR TREATING LEUKODYSTROPHIES | BRIDGEBIO GENE THERAPY LLC (US) | 2026-02-19 | — | — | US | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| US-12292445-B2 | Methods of selecting subjects for treatment with metabolomic modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-06 | — | — | US | claimed |
| US-20250134811-A1 | ULTRAFLEXIBLE LIPOSOMES IN GEL FORMULATION | UNIV NEW YORK STATE RES FOUND (US) | 2025-05-01 | — | — | US | claimed |
| US-20250003930-A1 | METHOD FOR ANALYZING AMINO ACIDS AND/OR ACYLCARNITINES | SHIMADZU CORPORATION (JP) | 2025-01-02 | — | — | US | claimed |
| CN-119224197-A | Method for analyzing amino acid and/or acyl carnitine | 株式会社岛津制作所 | 2024-12-31 | — | — | CN | claimed |
| CN-119165074-A | NSCLC patient typing and third generation EGFR-TKI efficacy prediction model based on T790M mutation of plasma metabolite | 中国医学科学院北京协和医院 | 2024-12-20 | — | — | CN | claimed |
| EP-4463139-A2 | ULTRAFLEXIBLE LIPOSOMES IN GEL FORMULATION | The Research Foundation for The State University of New York (US) | 2024-11-20 | — | — | EP | claimed |
| CN-118813788-A | Biomarker for detecting or judging osteoporosis or osteoporosis disease risk and application thereof | 上海中医药大学附属龙华医院 | 2024-10-22 | — | — | CN | claimed |
| CN-118731196-A | Qualitative and quantitative detection and analysis method and system for acyl carnitine and compound thereof | 复旦大学 | 2024-10-01 | — | — | CN | claimed |
| US-6165976-A | Therapeutic preparation for inhalation | ASTRA AKTIEBOLAG (SE) | 2000-12-26 | — | — | US | claimed |
| US-5830853-A | ADMINISTERING INSULIN AND ABSORPTION ENHANCER USING A DRY POWDER INHALER | ASTRA AKTIEBOLAG (SE) | 1998-11-03 | — | — | US | claimed |
| EP-0215697-B1 | ACYLCARNITINES AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL COMPARTMENTS | MERCK & CO. INC. (US) | 1992-03-25 | — | — | EP | claimed |
| US-4963525-A | POLYPEPTIDES | MERCK & CO., INC. (US) | 1990-10-16 | — | — | US | claimed |
| EP-0162764-B1 | COMPOSITION AND METHOD FOR ENHANCING ABSORPTION OF DRUGS FROM GASTROINTESTINAL TRACT USING ACYLCARNITINES | MERCK & CO. INC. (US) | 1989-08-09 | — | — | EP | claimed |
| US-4847298-A | DOPA COMPOUNDS OR ANTIBIOTICS | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | claimed |
| US-4731360-A | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments | MERCK & CO., INC. (US) | 1988-03-15 | — | — | US | claimed |
| EP-0215697-A2 | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments | MERCK & CO. INC. (US) | 1987-03-25 | — | — | EP | claimed |
| EP-0162764-A1 | Composition and method for enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | MERCK & CO. INC. (US) | 1985-11-27 | — | — | EP | claimed |
| US-4537772-A | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | MERCK & CO., INC. (US) | 1985-08-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048146-A1 | METHODS AND COMPOSITIONS FOR TREATING LEUKODYSTROPHIES | SPPL2A, PMP22, ATXN2L | MAPT 124/4885MEN1 3989/4885KMT2A 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.